Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Pancreas Cancer
79%
Malignant Neoplasm
67%
Neoplasm
66%
Neoadjuvant Therapy
43%
Adenocarcinoma
38%
Disease
30%
Cancer
30%
Systemic Therapy
29%
Systematic Review
24%
Intervention Study
23%
Immunofluorescence
21%
Antibody-Drug Conjugate
19%
Cancer Epidemiology
19%
Cancer Therapy
19%
Cell Population
19%
Immunosuppressive Drug
19%
Pancreas Tumor
19%
DNA Damage Response
19%
Phlebothrombosis
19%
Placebo
19%
Nutritional Assessment
19%
Microtubule
19%
Conjugate
19%
Stromal Cell
19%
Magnetic Resonance Imaging
19%
Geranyltransferase
19%
Cancer Biomarkers
19%
Drug Dose Reduction
19%
Stereotactic Radiotherapy
19%
Circulating Tumor DNA
19%
Liquid Biopsy
19%
DNA Template
17%
Targeted Therapy
17%
Clinical Trial
16%
Immunocompetent Cell
16%
Methionine Sulfoxide Reductase A
16%
Anticoagulation
15%
Thrombosis
15%
Tumor Microenvironment
15%
Anticarcinogen
14%
Immunotherapy
14%
Monoclonal Antibody
14%
Radiation Therapy
12%
Epirubicin
11%
Clinician
10%
Fatty Liver
9%
Bile Duct
9%
Ampulla of Vater
9%
Zoledronic Acid
9%
Keyphrases
Pancreatic Cancer
68%
Glycemic Variability
38%
Colon Cancer
38%
Pancreatic Ductal Adenocarcinoma
38%
Early Cancer Detection
32%
Systemic Therapy
29%
Type 2 Diabetes Mellitus (T2DM)
26%
High-risk Individuals
25%
Adult Patients
21%
Cachexia
19%
Cancer Surveillance
19%
Racial-ethnic
19%
Adjuvant Chemotherapy
19%
Chemotherapy Dose Intensity
19%
Lymphoma
19%
Study Identification
19%
Signaling Axis
19%
Splanchnic Vein Thrombosis
19%
Factor XI Deficiency
19%
Peripartum Management
19%
Postpartum Management
19%
Cancer Cachexia
19%
Epigenetic Priming
19%
Resectable Gastric Adenocarcinoma
19%
Pancreatic Adenocarcinoma
19%
MRI Screening
19%
Advanced Gastroesophageal Cancer
19%
Obese Adults
19%
Consensus Statement
19%
Guideline Update
19%
ASCO Guidelines
19%
Targeted Therapy
19%
Gender Disparity
19%
Patients with Cancer
19%
NADPH Oxidase 4 (NOX4)
19%
Multiplexed Immunofluorescence
19%
Coefficient of Variation
18%
Cancer Patients
14%
Survival Rate
12%
Obese Patients
12%
Adult Cancer
12%
United States
12%
Chemotherapy
11%
Cancer Causes
9%
Cancer Mortality
9%
Working Diagnosis
9%
Sirtuin 1 (SIRT1)
9%
Treatment Options
9%
Improved Patient Outcomes
9%
Locally Advanced
9%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
85%
Neoplasm
63%
Chemotherapy
59%
Disease
48%
Pancreas Adenocarcinoma
38%
Biological Marker
25%
Intervention Study
21%
Pancreas Cancer
21%
Geranyltransferase
19%
Placebo
19%
Esophageal Adenocarcinoma
19%
Immunosuppressive Agent
19%
Antibody Drug Conjugate
19%
Stomach Adenocarcinoma
19%
Pancreas Tumor
19%
Adenocarcinoma
19%
Chemotherapy Induced Nausea and Vomiting
19%
2,5-Dimethoxy-4-iodoamphetamine
19%
Microtubule Inhibitors
19%
Azacitidine
19%
Monoclonal Antibody
14%
Clinical Trial
12%
Anticarcinogen
11%
Immunotherapy
11%
Survival Rate
9%
Oxaliplatin
9%
Capecitabine
9%
Epirubicin
9%
Zoledronic Acid
9%
Fatty Liver
8%
Tumor Necrosis
7%
Bone Marrow Suppression
6%